1 |
Ahlawat SK, Sachdev A. Hypokalaemic paralysis. Postgrad Med J. 1999; 75(882):193-7.
pmid: 10715756
|
2 |
Maripuri S, Grande JP, Osborn TG, Fervenza FC, Matteson EL, Donadio JV, et al. Renal involvement in primary Sjögren’s syndrome: a clinicopathologic study. Clin J Am Soc Nephrol. 2009; 4(9):1423-31.
doi: 10.2215/CJN.00980209
|
3 |
François H, Mariette X. Renal involvement in primary Sjögren syndrome. Nat Rev Nephrol. 2016; 12(2):82-93.
doi: 10.1038/nrneph.2015.174
pmid: 26568188
|
4 |
Brito-Zeron P, Theander E, Baldini C, Seror R, Retamozo S, Quartuccio L, et al. Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol. 2016; 12(2):137-56.
doi: 10.1586/1744666X.2016.1109449
|
5 |
Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American college of rheumatology/European league against rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017; 69(1):35-45.
doi: 10.1002/art.v69.1
|
6 |
Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, et al. Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015; 14(11):1019-22.
doi: 10.1016/j.autrev.2015.07.002
pmid: 26162302
|
7 |
Venables PJ. Management of patients presenting with Sjogren’s syndrome. Best Pract Res Clin Rheumatol. 2006; 20(4):791-807.
doi: 10.1016/j.berh.2006.05.003
|